Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(50.0%)
N/A
2(50.0%)
4Total
Phase 4(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04960319Not ApplicableUnknown

Rotablation vs Intravascular Lithotripsy in Calcified Coronary Lesions

Role: lead

NCT01583608Completed

ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Role: lead

NCT01305174Phase 4Terminated

Iliac, Common and External (ICE) Artery Stent Trial

Role: lead

NCT01915420Unknown

The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions

Role: lead

NCT01305070Phase 4Completed

Standard Balloon Angioplasty Versus Angioplasty With a Paclitaxel-eluting Balloon for Femoral Artery In-stent Restenosis

Role: lead

NCT01067885Not ApplicableCompleted

A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery

Role: lead

All 6 trials loaded